

Two ovarian cancer clinical trials to be available (Broadcast)

At OSF HealthCare Cancer Institute

INTRO:

EVERY SEPTEMBER – A GREATER FOCUS IS GIVEN TO OVARIAN CANCER... HOPING TO INCREASE AWARENESS ABOUT THE DISEASE... ALONG WITH WARNING SIGNS AND SYMPTOMS. ACCORDING TO THE AMERICAN CANCER SOCIETY – NEARLY 21-THOUSAND WOMEN WILL RECEIVE A NEW OVARIAN CANCER DIAGNOSIS IN 2025... ALMOST 13-THOUSAND WILL DIE FROM OVARIAN CANCER.

TAKE VO

LEADING THE CHARGE FOR CANCER CARE ACROSS THE REGION... OSF HEALTHCARE CANCER INSTITUTE IN PEORIA WILL BE OFFERING TWO OVARIAN CANCER CLINICAL TRIALS FOR PATIENTS. THE FIRST LAUNCHED THIS MONTH.

THE FIRST TRIAL – GIVES SELECT OVARIAN CANCER PATIENTS THE OPTION TO RECEIVE AN ANTIBODY DRUG CONJUGATE THAT TARGETS SPECIFIC CANCER CELLS. OSF CANCER INSTITUTE WILL BE A PART OF A COOPERATIVE GROUP TRIAL WITH THE G-O-G PARTNERS PROGRAM... INCLUDING MULTIPLE SITES ACROSS THE COUNTRY.

MICHELLE ROWLAND – A GYNECOLOGIC ONCOLOGIST WITH OSF HEALTHCARE – SAYS IT WILL ALLOW FOR LOWER DOSING... WHICH IS AN IMPROVEMENT FROM TRADITIONAL CHEMOTHERAPY. THIS CREATES FEWER SIDE EFFECTS... WHILE STILL BEING MORE EFFECTIVE.

TAKE SOT | DR. MICHELLE ROWLAND | GYNECOLOGIC ONCOLOGIST | OSF HEALTHCARE

"Recently in patients who have had their ovarian cancer recur, we've noted that we have a new drug called [mirvetuximab soravtansine](#) with Carboplatin, which works really well in those patients. This is now a trial looking at using this drug in cancer patients with a new diagnosis," Dr. Rowland explains. "This changes what the standard of care is and hopefully improves the responses we're getting and lessening the side effects of their treatment. This will be for patients who are newly diagnosed with ovarian cancer and require chemotherapy."

VO TAG

DR. ROWLAND SAYS OSF CANCER INSTITUTE IS CURRENTLY LOOKING FOR PATIENTS WITH A NEW OVARIAN CANCER DIAGNOSIS FOR THE UPCOMING TRIAL WHO HAS NOT RECEIVED CHEMOTHERAPY. A SECOND TRIAL IS EXPECTED TO LAUNCH IN LATE 2025.